Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.48 |
| ▸ | MAG | P20916 | 8/20 | 0.47 |
| ▸ | SELE | P16581 | 4/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312027 | 1.00 | SIGLEC7 (0.48) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL12197063 | 1.00 | SIGLEC7 (0.48) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL17195818 | 1.00 | SIGLEC7 (0.48) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL15849094 | 1.00 | SIGLEC7 (0.48) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL12197067 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL16232773 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL16312031 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL12197073 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL16312028 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL15849100 | 0.99 | SIGLEC7 (0.47) | SIGLEC7MAGSELESELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937264-B2 | Glycosylated polypeptide and drug composition containing said polypeptide | GLYTECH, INC. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9879097-B2 | Method for producing activated sugar chain derivative and activated sugar chain derivative produced therefrom | GLYTECH, INC. (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9802996-B2 | Glycosylated polypeptide and drug composition containing said polypeptide | GLYTECH, INC. (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20170157260-A1 | Glycosylated Polypeptide and Drug Composition Containing said Polypeptide | GLYTECH, INC. (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20160368961-A1 | Glycosylated Polypeptide and Drug Composition Containing said Polypeptide | GLYTECH, INC. (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9441024-B2 | Glycosylated polypeptide and drug composition containing said polypeptide | GLYTECH, INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160075799-A1 | A METHOD FOR PRODUCING ACTIVATED SUGAR CHAIN DERIVATIVE AND ACTIVATED SUGAR CHAIN DERIVATIVE PRODUCED THEREFROM | GLYTECH INC (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160052987-A1 | POLYPEPTIDE HAVING SIALYLATED SUGAR CHAINS ATTACHED THERETO | GLYTECH, INC. (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20140315800-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GLYTECH, INC. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20120114595-A1 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20110313136-A1 | IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110195897-A1 | GLYCOSYLATED GLP-1 PEPTIDE | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313136-A1 | IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME | FCGR1A, FCGR2A, FCGR3B | SIGLEC7 11/4885MAG 332/4885SELE 532/4885 |
| US-20110195897-A1 | GLYCOSYLATED GLP-1 PEPTIDE | GLP1R, GIPR, IAPP | SIGLEC7 102/4885MAG 1399/4885SELE 200/4885 |
| US-20170157260-A1 | Glycosylated Polypeptide and Drug Composition Containing said Polypeptide | GIPR, SSTR4, SSTR3 | SIGLEC7 100/4885MAG 784/4885SELE 428/4885 |
| US-20160052987-A1 | POLYPEPTIDE HAVING SIALYLATED SUGAR CHAINS ATTACHED THERETO | IFNAR1, FUT4, SIGLEC7 | SIGLEC7 3/4885MAG 1739/4885SELE 316/4885 |
| US-20160075799-A1 | A METHOD FOR PRODUCING ACTIVATED SUGAR CHAIN DERIVATIVE AND ACTIVATED SUGAR CHAIN DERIVATIVE PRODUCED THEREFROM | SI, ASNS, MGAM | SIGLEC7 111/4885MAG 2773/4885SELE 3065/4885 |
| US-20120114595-A1 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME | SIGLEC7, ENGASE, SIGLEC9 | SIGLEC7 1/4885MAG 319/4885SELE 50/4885 |
| US-20160368961-A1 | Glycosylated Polypeptide and Drug Composition Containing said Polypeptide | GIPR, SSTR3, SSTR4 | SIGLEC7 92/4885MAG 766/4885SELE 440/4885 |
| US-20140315800-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GIPR, SSTR3, SSTR4 | SIGLEC7 92/4885MAG 766/4885SELE 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.